First of all, a very happy new year to you all! It’s that time when you make yourself all sorts of promises and resolutions. You look forward to a fresh start and lay out all the things you will do differently this year compared to last. Any chance your list includes a resolution to invest more in the corporate brand?
The pharmaceutical industry is experiencing a time of unprecedented challenge. Patent expiries, regulatory issues, and increased pressures from healthcare providers have combined to create an environment where the sector is associated with lower growth and higher risk. Clearly focusing on reputation should be everything for you right now? Or should it?
In an industry subject to a lot of scrutiny, we hear the term ‘Corporate reputation’ used a lot. It is often used alongside ‘corporate brand,’ perhaps even in the same sentence to mean the same thing. The CEC’s quantitative research from ‘Building Stakeholder Preference through the Corporate Brand’, however, confirms that reputation and brand are two means to two very different ends. The end goal for reputation is stakeholder acceptance (i.e., “would I consider doing business with you?”), and the end goal for corporate brand management is stakeholder preference (i.e., “would I as a health care professional choose to prescribe your drug in preference to your competitor’s?”) Read More »







I am not a journalist (but I blog and tweet). And in most cases, I am not a shareholder (but I could be once my next